What is Alkem Laboratories Ltd's PE ratio?

Alkem Laboratories Ltd trades at a P/E ratio of 27.60.

What is Alkem Laboratories Ltd's market cap?

Alkem Laboratories Ltd's market capitalisation is ₹67,357 Cr.

When are Alkem Laboratories Ltd's next results?

Alkem Laboratories Ltd's next earnings date is 14 Aug '26.

What is Alkem Laboratories Ltd's ROE?

Alkem Laboratories Ltd's return on equity (ROE) is 18.9%.

What sector is Alkem Laboratories Ltd in?

Alkem Laboratories Ltd (ALKEM) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Alkem Laboratories Ltd (ALKEM)

₹5,633.50

Mkt cap

₹67,357 Cr

P/E ratio

27.60

P/B

4.87

Div yield

0.80%

ROE

18.90%

ROCE

21.20%

EPS (TTM)

₹204.11

Book value

₹1,156

52W range

4,764–5,890

Sector

Healthcare

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

NSE ALKEMBSE 539523www.alkemlabs.com

Health check

Constructive

ValuationCheap

ProfitabilityStrong

GrowthModerate

TechnicalsNeutral

52-week range

−4.35% from high

₹5,634

₹4,764+18.25% from low₹5,890

Current

₹5,633.50

Prev close

₹5,642.00

Day

−0.15%

Price performance

−0.15%

−0.35%

+3.84%

+7.61%

−1.52%

+12.25%

YTD

+0.73%

Financials

F

Revenue, profit & margin

P/E ratio

27.6×

ALKEM is 19% below the sector median of 34.0×

ALKEM27.6×

Sector median34.0×

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	2,903	2,968	3,440	3,324	2,936	3,032	3,415	3,374	3,144	3,371	4,001	3,737	3,603
Expenses	2,549	2,579	2,693	2,616	2,534	2,423	2,662	2,615	2,752	2,632	3,080	2,909	3,086
Operating Profit	353	389	747	708	402	609	753	759	391	739	921	828	517
OPM %	12%	13%	22%	21%	14%	20%	22%	23%	12%	22%	23%	22%	14%
Other Income	-34	66	6	42	76	120	134	93	146	149	104	90	65
Interest	29	30	30	25	27	29	28	36	28	30	35	42	54
Depreciation	78	72	74	70	83	80	79	85	112	88	94	95	106
Profit before tax	212	353	648	655	367	619	780	731	396	771	896	781	423
Tax %	68%	18%	5%	8%	17%	11%	10%	12%	18%	13%	13%	16%	40%
Net Profit	68	288	615	604	304	550	702	641	322	668	779	653	251
EPS in Rs	5.94	23.98	51.90	49.76	24.55	45.60	57.60	52.34	25.58	55.56	63.99	53.19	19.78
Raw PDF

Earnings

EResults dates & reactions

Next results

14 Aug '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move −0.38% · closed higher next day 16 of last 41

	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25†	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Broadcast	10 Aug '23◦	7 Nov '23◦	9 Feb '24◦	29 May '24◦	9 Aug '24◦	13 Nov '24◦	7 Feb '25◦	27 Jun '25	12 Aug '25	13 Nov '25	13 Feb '26	28 May '26◦
Earnings day	−7.71%	+5.10%	−3.35%	−6.00%	−1.41%	−0.83%	−6.80%	+1.35%	+6.29%	−0.73%	−7.97%	+0.85%
+1 day	−8.35%	+6.34%	−0.65%	−8.59%	−1.51%	−1.01%	−8.69%	+2.02%	+11.23%	−0.78%	−6.64%	−2.51%
+5 days	−7.69%	+8.29%	+2.70%	−7.75%	−1.10%	−1.67%	−6.93%	+0.94%	+11.32%	−1.17%	−8.15%	−3.67%
+15 days	−11.85%	+15.41%	−3.81%	−2.53%	+5.38%	−1.55%	−10.42%	+3.25%	+9.43%	−1.88%	−6.99%	−1.43%
+30 days	−14.75%	+22.03%	−6.08%	−1.21%	+4.31%	+1.13%	−2.88%	−1.59%	+13.70%	−4.03%	−10.66%	+2.12%
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	PDF	PDF	XBRL	XBRL

Corporate actions

CLast 6 months

Kind	Value	Ex-date	Record
dividend Interim Dividend - Rs 43 Per Share	43.00	20 Feb '26	20 Feb '26

Shareholding

Sas of Jun 2026

49.70%Promoter

Promoters49.70%1.50

FIIs10.42%0.27

DIIs22.64%1.25

Public17.25%

Ownership trend

Peers

P8 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
Sun Pharma.Inds.	₹1,941.10	37.48	4,65,735	0.82%	2,710	+13.58%	14,612	+12.76%	20.53%
Divi's Lab.	₹7,248.50	73.36	1,92,425	0.41%	751	+13.44%	2,831	+9.52%	21.97%
Torrent Pharma.	₹4,961.50	86.11	1,88,720	0.77%	364	−20.58%	4,197	+41.84%	15.19%
Cipla	₹1,410.60	31.84	1,13,955	0.92%	786	−39.19%	7,119	+2.33%	15.49%
Zydus Lifesci.	₹1,108.70	20.38	1,10,593	0.09%	1,341	+21.92%	7,587	+16.22%	21.14%
Lupin	₹2,370.50	19.06	1,08,387	0.76%	1,469	+101.49%	7,475	+31.89%	29.93%
Mankind Pharma	₹2,507.20	51.44	1,03,559	0.04%	559	+34.23%	3,443	+11.81%	13.53%
Alkem Lab	₹5,633.50	27.65	67,357	0.80%	251	+2.04%	3,603	+14.62%	21.23%
Median: 157 Co.	₹432.05	34.03	1,978	0.10%	15	+28.10%	176	+17.66%	15.10%

Filings

D

Annual reports15

Financial Year 2025bse Financial Year 2024web Financial Year 2024bse Financial Year 2023web Financial Year 2023bse Financial Year 2022bse Financial Year 2021bse Financial Year 2020bse Financial Year 2019bse Financial Year 2018bse Financial Year 2017bse Financial Year 2016bse Financial Year 2013bse Financial Year 2012bse Financial Year 2011bse

Credit ratings6

Rating update 8 Julcrisil Rating update 24 Febcrisil Rating update 6 Febfitch Rating update 5 Jancare Rating update 15 Sep 2025crisil Rating update 7 Feb 2025fitch

Announcements5

Announcement under Regulation 30 (LODR)-Change in Management 1d - Dr. Jitendra Singh Huda resigned as Senior Management Personnel effective 23 July 2026.Board Meeting Intimation for Notice Of Meeting Of The Board Of The Company. 21 Jul - Board meeting on 14 August 2026 to approve Q1 FY27 standalone and consolidated results.Announcement under Regulation 30 (LODR)-Updates on Acquisition 17 Jul - Alkem Medtech completed acquisition of 51%-55% stake in Occlutech, making it a step-down subsidiary.Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Jul - Please find attached herewith Newspaper Publication.Announcement under Regulation 30 (LODR)-Acquisition 16 Jul - Alkem Laboratories acquired rights shares in Alkem Medtech for ₹1,100 crore on 15 July 2026.